Stroke RSS Page 5

Filtered By:
Condition: Atrial Fibrillation
Countries: UK Health

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 94 results found since Jan 2013.

Characterizing the Penumbras of White Matter Hyperintensities and Their Associations With Cognitive Function in Patients With Subcortical Vascular Mild Cognitive Impairment
Conclusion In this study, reduced CBF and FA and increased MD in the inner NAWM layers for both PVWMH and DWMH suggested extensive WM alterations beyond the visible WM lesions commonly observed on clinical MRI of svMCI subjects. CBF penumbras cover more extensive WM at risk than DTI penumbras, suggesting the likelihood that compromised CBF precedes white matter integrity changes, and CBF penumbras may be a potential target for the prevention of further microstructural white matter damage. The imaging parameters investigated, however, did not correlate to cognition. Author Contributions YZ, QX, and XG conceived and desig...
Source: Frontiers in Neurology - April 11, 2019 Category: Neurology Source Type: research

Contemporary prevalence of carotid stenosis in patients presenting with ischaemic stroke.
CONCLUSION: Carotid stenosis is common, affecting one in five patients presenting with stroke or TIA. Careful MDT discussion may avoid unnecessary intervention and should be the standard of care. PMID: 30938840 [PubMed - as supplied by publisher]
Source: The British Journal of Surgery - April 1, 2019 Category: Surgery Authors: Cheng SF, Brown MM, Simister RJ, Richards T Tags: Br J Surg Source Type: research

Substantial Cardiovascular Morbidity in Adults with Lower-Complexity Congenital Heart Disease.
CONCLUSIONS: Individuals with lower-complexity ACHD had higher burden of adverse cardiovascular events relative to the general population that was unaccounted for by conventional cardiovascular risk factors. These findings highlight the need for closer surveillance of patients with mild to moderate ACHD and further investigation into management and mechanisms of cardiovascular risk unique to this growing population of high-risk adults. PMID: 30813762 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2019 Category: Cardiology Authors: Saha P, Potiny P, Rigdon J, Morello M, Tcheandjieu C, Romfh A, Fernandes SM, McElhinney DB, Bernstein D, Lui GK, Shaw GM, Ingelsson E, Priest JR Tags: Circulation Source Type: research

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
This study details the design of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study – a postauthorization observational study, which is part of the postapproval plan for edoxaban agreed with the European Medicines Agency. Methods The ETNA-AF-Europe study (Clinicaltrials.gov: NCT02944019) is a multicenter, prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated with edoxaban from 852 sites across 10 European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland,...
Source: Journal of Cardiovascular Medicine - January 3, 2019 Category: Cardiology Tags: Research articles: Trial design Source Type: research

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
ConclusionsAll DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban exhibited the highest bleeding risks. Observed differences in the risks of all ‐cause mortality, myocardial infarction, and pulmonary embolism warrant further research.
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Tanja Mueller, Samantha Alvarez ‐Madrazo, Chris Robertson, Olivia Wu, Marion Bennie Tags: ORIGINAL ARTICLE Source Type: research

Effectiveness and safety of 110 or 150 mg dabigatran versus vitamin K antagonists in non ‐valvular atrial fibrillation.
ConclusionIn real life D110 and D150 were at least as effective and safer than VKA.
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Patrick Blin, Caroline Dureau ‐Pournin, Yves Cottin, Jacques Bénichou, Patrick Mismetti, Abdelilah Abouelfath, Regis Lassalle, Cécile Droz, Nicholas Moore Tags: ORIGINAL ARTICLE Source Type: research

Barriers to a software reminder system for risk assessment of stroke in atrial fibrillation: a process evaluation of a cluster randomised trial in general practice.
CONCLUSION: Automated risk assessment for stroke in atrial fibrillation and prompting during consultations are feasible and generally acceptable, but did not overcome concerns about frailty and risk of haemorrhage as barriers to anticoagulant uptake. PMID: 30397015 [PubMed - as supplied by publisher]
Source: The British Journal of General Practice - November 5, 2018 Category: Primary Care Authors: Holt TA, Dalton AR, Kirkpatrick S, Hislop J, Marshall T, Fay M, Qureshi N, Lasserson DS, Kearley K, Mollison J, Yu LM, Fitzmaurice D, Hobbs FR Tags: Br J Gen Pract Source Type: research

Patients ’ Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis
DiscussionAlthough the relative impact of convenience on therapy value is small, patients have different preferences for options within convenience criteria. Besides considerations on safety and effectiveness, physicians should also discuss attributes of convenience with patients, as it can be assumed that alignment to patient preferences in drug prescription and better patient education could result in higher adherence.
Source: American Journal of Cardiovascular Drugs - August 22, 2018 Category: Cardiology Source Type: research

Screening, optimization, support: a call for stroke prevention in atrial fibrillation.
PMID: 30070947 [PubMed - in process]
Source: British Journal of Hospital Medicine - August 2, 2018 Category: Internal Medicine Authors: Induruwa I, Liu W, Khadjooi K Tags: Br J Hosp Med (Lond) Source Type: research

Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke Original Articles
Conclusions: This result represents the first genetic evidence in a large cohort for the protective effect of PCSK9 inhibition on ischemic stroke and corroborates exploratory evidence from clinical trials. PCSK9 inhibition was not associated with variables other than those related to LDL (low-density lipoprotein) cholesterol, atherosclerosis, and type 2 diabetes mellitus, suggesting that other effects are either small or absent.
Source: Circulation: Cardiovascular Genetics - July 11, 2018 Category: Cardiology Authors: Rao, A. S., Lindholm, D., Rivas, M. A., Knowles, J. W., Montgomery, S. B., Ingelsson, E. Tags: Cardiovascular Disease, Diabetes, Type 2, Genetic, Association Studies, Ischemic Stroke Original Articles Source Type: research

Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study
This study is registered with ClinicalTrials.gov, number NCT02513316.FindingsBetween Aug 4, 2011, and July 31, 2015, we recruited 1490 participants of whom follow-up data were available for 1447 (97%), over a mean period of 850 days (SD 373; 3366 patient-years). The symptomatic intracranial haemorrhage rate in patients with cerebral microbleeds was 9·8 per 1000 patient-years (95% CI 4·0–20·3) compared with 2·6 per 1000 patient-years (95% CI 1·1–5·4) in those without cerebral microbleeds (adjusted hazard ratio 3·67, 95% CI 1·27–10·60). Compared with the HAS-BLED score alone (C-index 0·41, 95% CI 0·29–0·5...
Source: The Lancet Neurology - July 10, 2018 Category: Neurology Source Type: research

Pages: 1 2 3 4 5 6 7